White House Reviews New Peptide Policy

The Trump administration is advancing a proposal that could make certain peptide injections more accessible through specialty pharmacies, marking another step in Health Secretary Robert F. Kennedy Jr.’s efforts to loosen restrictions on wellness products.

The Department of Health and Human Services submitted an interim peptide access policy to the White House for review, according to a government website posting on Thursday. The proposal was sent to the Office of Management and Budget, which reviews federal regulations with potentially significant economic effects.

The filing does not provide specific details about which peptides could be covered. However, people familiar with the proposal said it is intended to allow pharmacies to temporarily compound some popular products, including BPC-157, a substance promoted by wellness influencers for muscle development and injury recovery.

The proposal could use enforcement discretion, allowing the Food and Drug Administration to refrain from targeting pharmacies that produce certain peptides. The approach would not necessarily mean that the products have received formal FDA approval or have been established as safe and effective.

Kennedy Pushes to Expand Access to Wellness Products

Peptides are short chains of amino acids that serve as building blocks for proteins and play roles in biological processes, including hormone signaling, metabolism and tissue repair. Some peptide-based medicines have undergone extensive testing and are approved for specific medical uses, including treatments for diabetes and weight management.

The products at the center of the administration’s proposal are different. Many have not undergone the rigorous testing required for approved medications, and much of the available research cited in the source report comes from animal studies.

Despite the limited evidence, certain peptides have gained popularity among consumers seeking to build muscle, improve their appearance, increase energy or support recovery from injuries. These uses are not approved by the FDA for the products discussed in the report.

Kennedy has previously criticized the FDA’s restrictions on peptides and other wellness products. As health secretary, he has argued that allowing U.S. compounding pharmacies to sell certain peptides could provide an alternative to products obtained through gray-market channels, including those sourced from China and promoted through online platforms.

FDA Safety Concerns Complicate the Proposal

The FDA previously placed BPC-157 and more than a dozen other injectable peptides on a list of substances considered too risky for compounding by pharmacies. The agency has cited potential dangers including contamination, allergic reactions and tumor growth.

Earlier this year, Kennedy directed the agency to reconsider restrictions on a selection of peptides promoted by wellness influencers and fitness personalities.

In July, an external FDA advisory panel recommended removing restrictions on six of the seven peptides presented for review. That recommendation differed from the conclusions of FDA staff scientists, who maintained that the substances had not been sufficiently studied to establish their safety and effectiveness.

The disagreement highlights the tension between expanding consumer access and maintaining evidence-based safeguards for products intended for injection. Although the advisory panel’s recommendations could influence future policy, they do not independently establish that the peptides are safe or effective.

Enforcement Discretion Could Accelerate Access

Formally adding peptides to the FDA’s list of substances considered eligible for compounding would require federal rulemaking, a process that can take years and includes multiple opportunities for public comment.

The interim policy under review could offer a faster, temporary route by signaling that the FDA would not prioritize enforcement against pharmacies producing selected peptides under the proposed approach. The source report did not establish whether the administration still intends to pursue the formal rulemaking process.

The proposal has already received support from some figures associated with the Make America Healthy Again movement, including wellness businesses that sell peptide products. Supporters frame the issue as a question of consumer choice and medical freedom, while critics point to the limited clinical evidence and potential health risks.

The policy’s final scope, implementation timeline and regulatory conditions remain uncertain.

Telehealth Companies See Commercial Opportunity

The peptide debate is also attracting attention from companies looking to expand their offerings in the growing wellness and telehealth markets.

Hims & Hers and Noom have recently announced plans to offer peptides to customers if federal policy allows broader access. Their interest reflects the commercial potential of products marketed to consumers focused on fitness, recovery, longevity and general wellness.

Wall Street analysts estimate that the peptide market could eventually be worth between $2 billion and $3 billion. However, that opportunity depends in part on the regulatory environment, the products that become eligible for compounding and the extent to which consumer demand translates into sustainable revenue.

For telehealth providers, a more permissive policy could open a new category of services. At the same time, questions about clinical evidence, product quality, liability and regulatory compliance could shape how quickly businesses can enter the market.

What Investors and Consumers Should Watch Next

The immediate focus is on the White House review and whether the administration releases further details about the peptides covered by the interim policy. Investors will also be watching for clarification on the FDA’s enforcement approach and whether formal rulemaking will follow.

For companies considering peptide offerings, the distinction between temporary enforcement discretion and formal authorization will be especially important. Any expansion of access could create commercial opportunities, but regulatory uncertainty and unresolved safety questions remain significant constraints.

Consumers should also distinguish between peptides that are approved medicines for specific indications and products that have not demonstrated safety and effectiveness through adequate clinical testing. A policy change allowing certain pharmacy compounding would not, by itself, establish that an injectable peptide is safe, effective or appropriate for an individual.